TCJL37 是一种有效的，选择性的，口服生物可利用的TYK2抑制剂，Ki为 1.6 nM。TCJL37 可用于炎症性肠病 (IBD) 的研究。

TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a K i of 1.6 nM. TCJL37 is able to be used for the research of inflammatory bowel diseases (IBD) [1].

In cell-based assays, TCJL37 (Compound 37) exhibits IL-12 pSTAT4 EC 50 of 224 nM. TCJL37 exhibits EC 50 s of 168 nM and 737 nM In human peripheral blood mononuclear cells (PBMC) and human whole blood assay, respectively [1].

TCJL37 demonstrates excellent oral exposure in CD-1 mice following oral administration (100 mg/kg). TCJL37 exhibits low clearance (1.0 mL/min/kg) in rat [1].

1258294-34-6

C17H11ClF2N4O2

376.74

Compound T4666

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years